Alpha Tau Medical

08/01/2026

Excited to be in San Francisco for 2026!

We are gearing up to attend the Gastrointestinal Cancers Symposium, in what promises to be a highly engaging and fascinating conference. A highlight for us this year will be the presentation by Dr. Corey Miller of the latest Alpha DaRT® results from our trial in Montreal for pancreatic cancer, which we are very excited to share with top leaders in this important field.
Our Business Development Manager, Michael Tolub, is also on-site and eager to connect for those who wish to learn more about our exciting clinical trial program.
Please feel free to reach out here or direct message us to coordinate a time to meet with Michael or Dr. Miller.
Looking forward to meeting you!

06/01/2026

Alpha Tau Medical today announced the release of final results from its first-in-human study in Montreal, Canada exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma (PDAC). The results have been published as two abstracts and will be presented at the upcoming 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, January 8 – 10, 2026.

“We are very excited about the results of the study, in which we were the first clinicians to deliver Alpha DaRT via ultrasound into the pancreas”, added Dr. Corey Miller. “The results indicate that Alpha DaRT is a technically feasible treatment of pancreatic cancer, with a strong safety profile and encouraging local disease control. We look forward to further exploration of the use of Alpha DaRT for PDAC patients in the IMPACT trial as well as future trials, with the potential to generate a meaningful data set focused on a specific patient population with newly diagnosed disease”.



For the full announcement, please read:

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Showcasing Immune-Preservation and High Disease Control

05/01/2026

Alpha Tau Medical today announced the submission of the first module of its pre-market approval ( ) application to the U.S. Food and Drug Administration ( ), following the FDA’s previous decision to allow the Company to use the more flexible modular approach.

- Initial module submission marks an important milestone in the pre-market approval process -

- Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted -

- Module submitted in parallel to ex*****on of pivotal study (Recurrent SCC Treatment with Alpha DaRT Radiation Therapy), which is expected to complete recruiting patients in Q1 2026 -

For the full announcement, please read -

Alpha Tau announced the submission of the first module of its pre-market approval (PMA) application FDA

25/12/2025

First Alpha DaRT® Treatment at OSU featured in cleveland.com

Nice to see the world’s first use of Alpha DaRT technology in the brain featured in cleveland.com. It’s meaningful to see this important innovation recognized on a major platform, reinforcing both the urgent unmet need in treating recurrent and the promise of Alpha DaRT as a treatment approach, currently only available in .

https://www.cleveland.com/news/2025/12/brain-tumor-breakthrough-first-patient-receives-alpha-dart-radiation-at-osu.html

The James Cancer Hospital's innovative procedure places short-range radiation directly into glioblastoma tumors, addressing the urgent need for localized treatments with fewer side effects.

24/12/2025

18/12/2025

Alpha Tau Medical today announced that CEO U*i Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 11:15am PT / 2:15pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.

- The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones -

To see the full announcement, please read:

https://www.alphatau.com/single-post/alpha-tau-to-present-at-the-j-p-morgan-2026-healthcare-conference

14/12/2025

Raising Awareness for Difficult-to-Treat Cancers on Israel’s National Stage

We were pleased to see Alpha DaRT® featured on Israel’s Channel 13’s Stethoscope, a leading health program reaching a broad national audience. The segment included an interview with Prof. Aron Popovtzer, Director of the Sharett Oncology Institute at Hadassah Medical Center, and a key investigator in our ongoing clinical efforts.

Awareness plays a critical role in expanding access, especially for patients facing aggressive, treatment-resistant diseases such as pancreatic cancer. These public platforms help inform patients, families, and clinicians about clinical research opportunities that may not otherwise be visible.

Alpha Tau remains committed to advancing our clinical trial footprint in Israel and globally, working with leading medical centers like Hadassah to bring novel intratumoral therapies to more patients.
Watch the full segment here: https://www.youtube.com/watch?v=1h-FCPK1x9I

*Alpha DaRT is currently available only in the context of authorized clinical trials.

פרופ' אהרון פופובצר, מנהל המערך האונקולוגי, במרכז הרפואי הדסה. הגיע לתוכנית כדי להסביר על טיפול חדשני וממוקד לסרטן הלבלב.

10/12/2025

As we close out 2025, this past week has been a perfect snapshot of the pace, passion, and spirit that define Alpha Tau.

In the span of just a few days, we secured approval to launch our U.S. IDE pilot study in recurrent (our 5th IDE), had two abstracts accepted for presentation at the upcoming 2026 ASCO GI Symposium, contributed expert insights to a global HuffPost feature on cancer prevention, and, perhaps most meaningfully, treated the first patient ever with Alpha DaRT in the brain in our U.S. recurrent study.

This week is not an exception, it’s simply a week in the life of Alpha Tau. And if this is how 2025 ends, just wait for what’s coming in 2026.

To our incredible employees and our clinical partners across Japan, Israel, Europe, the U.S., and Canada: thank you.
Wishing everyone a wonderful holiday season, a Happy Hanukkah, and an inspiring and blessed New Year.

— U*i Sofer, CEO, Alpha Tau Medical

09/12/2025

Alpha Tau Medical today announced that the first patient has been treated in its pilot study for the treatment of patients with recurrent glioblastoma multiforme (GBM) using the Alpha DaRT technology.

The first patient was treated at The Ohio State University Center in Columbus, Ohio, by a multidisciplinary team led by Principal Investigator and RadiationOncologist Joshua D. Palmer, MD, Medicalphysicist Michael Degnan, MS, DABR and Neurosurgeon J. Bradley Elder, MD, using a novel delivery approach designed specifically for intracranial use.

Dr. Joshua Palmer, commented: “Patients with recurrent glioblastoma face one of the most difficult cancer diagnoses in medicine. There is an urgent unmet need for new therapeutic approaches that can be delivered locally while minimizing harm to surrounding healthy brain tissue. Intratumoral alpha-emitting radiotherapeutics such as Alpha DaRT offer a highly compelling novel scientific approach by delivering potent, short-range radiation precisely where it is needed most.”

Dr. J. Bradley Elder, who led the procedure with Dr. Palmer, added: “From a technical standpoint, this procedure demonstrated excellent feasibility. The novel delivery device allowed us to place the Alpha DaRT sources in a precise radial configuration that achieved more than 95% coverage of the tumor volume. Importantly, the system integrates seamlessly as an add-on to the standard brain navigation platform that I use routinely in surgery, making it simple to adopt without disrupting existing workflow.”

For the full announcement, please read: https://www.alphatau.com/single-post/alpha-tau-successfully-treats-first-patient-in-its-u-s-trial-for-patients-with-recurrent-glioblasto

08/12/2025

Cancer changes your life in an instant. When Yonatan Edvi was diagnosed with , he had to make difficult decisions about treatments, including participating in a pioneering clinical trial with Alpha DaRT. This is his story.
_______________________________________________________________________

My name is Yonatan Edvi. I am 47 years old, married with four children, and I live in Modiin. I currently manage a regional office at Maccabi Health Services, and previously, I served as an advisor to Prime Minister Benjamin Netanyahu for about seven years.

Three and a half years ago, I was diagnosed with lung cancer. I have never smoked and have generally been a healthy person. Until last year, I participated in triathlons. I discovered the cancer by chance after a race - I had bronchitis, and a chest X-ray revealed a suspicious spot that turned out to be cancer.

After having received extensive radiation to my lungs, I was still looking for a different solution. My oncologist referred me to Dr. Philip Blumenfeld and the Alpha DaRT clinical trial. I had heard about Alpha TAU a few years earlier, and I decided to join the trial based on my oncologist’s recommendation. I felt this was the rational option. Dr. Blumenfeld explained all the details of the treatment, and it seemed very simple and clear. The tumor’s location was also ideal for this approach. I had no doubts - if the doctor said to proceed, I went ahead, as part of a decision I got after being diagnosed, to trust my care giver. And this option felt right and promising.

The treatment was done in three stages. The first visit checked that a bronchoscope could reach the tumor. The second visit was the treatment itself, with insertion of radium-224 sources. The third visit checked the effect of the treatment. I was told that I was the second lung patient in the world to receive Alpha DaRT, so no one could predict exactly how I would feel afterward. I was out of commission for about two weeks. My urine changed color, and my body felt weak because of the radium-224 inside. I had undergone radiation before, but this treatment is designed to work from inside the tumor. It was a hard couple of weeks, but we are over it now.

I strongly recommend participating in the . For me, it was very successful. Compared with chemotherapy and conventional radiation, this was the least devastating option. I call Alpha DaRT the medicine of the future - it’s a treatment that doesn’t destroy your body. Luckily for me, follow-up PET scans showed a reduction in the tumor.

I am a satisfied patient, but of course, I hope no one ever needs this treatment.

Disclaimer: What is written reflects only the experience of the patient and does not guarantee similar outcomes or results for other patients.

07/12/2025

It’s not every day you have the opportunity to reach nearly 70 million people.

We’re proud to share that Alpha Tau Medical was recently featured in a widely read HuffPost article - also syndicated across Yahoo News - highlighting one of the most fundamental, yet often overlooked, aspects of cancer prevention: sun protection.

In the article, our Chief Medical Officer and practicing radiation oncologist, Dr. Robert Den, reinforced a simple but essential truth:
Skipping sunscreen significantly increases your risk of skin cancer, premature aging, and cumulative UV damage. Daily protection, combined with smart sun habits and regular skin checks, can quite literally save lives.

In an era where health trends spread rapidly, often driven by social media influencers, it’s more important than ever to be cautious about advice that isn’t grounded in medical science. Trends like avoiding sunscreen can be harmful, even when they sound “natural” or “wellness-focused.” When it comes to your health, trusted guidance should always come from qualified medical professionals.

At Alpha Tau, our mission is to fight cancer through innovative, targeted therapies like Alpha DaRT®, but we are just as committed to the importance of education, prevention, and early detection.

Social media is full of “health” advice nowadays — but a lot of it is hogwash or even harmful, according to experts.

04/12/2025

Alpha Tau Medical announced today that two abstracts have been accepted to the 2026 American Society of Clinical Oncology ( ) Gastrointestinal Cancers Symposium, to be held January 8-10, 2026 in San Francisco, California.

The abstracts, entitled “Feasibility, Safety and Efficacy of Endoscopic Ultrasound-Guided Alpha Radiotherapy for Advanced Pancreatic Cancer: A Pilot Study”, and “Inflammatory and Immune Marker Dynamics following Intratumoral Alpha DaRT for ”, will both be presented by investigators in the Company’s recently completed pancreatic cancer pilot trial in Montreal, Canada, by study Principal Investigator Corey Miller, MD, and by Kim Anh Ma, MD, respectively.

Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026JERUSALEM, December 4, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer...